Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Robert I. Haddad, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Chief, Division of Head and Neck Oncology
  • McGraw Chair in Head and Neck Oncology
  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Head and neck oncology

Diseases Treated

Contact Information

  • Appointments877-332-4294 (new)
    617-632-3090 (follow-up)
  • Office Phone Number617-632-3090
  • Fax617-632-4448

Bio

Dr Haddad received his MD Degree from St. Joseph University French School of Medicine in Beirut. He completed his residency in internal medicine at St Luke's Roosevelt Medical Center in New York City, and completed a fellowship in hematology oncology at the University of Maryland Cancer Center in Baltimore.

Board Certification:

  • Internal Medicine, 1998
  • Medical Oncology, 2001

Fellowship:

  • University of Maryland, Baltimore, Hematology & Oncology

Residency:

  • Saint Luke's - Roosevelt Hospital Center, Internal Medicine

Medical School:

  • Saint Joseph University Medical School

Research

Clinical Investigation of Head and Neck Cancer


As the Chief of the Division of Head and Neck Oncology, I care for patients with head and neck cancer and also supervise clinical trials involving these patients. They are typically treated in a multidisciplinary clinic in close collaboration with the Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC), the Department of Radiation Oncology at DFCI, dentistry, speech and swallow therapists, and oral surgery. I also conduct translational research in cooperation with Harvard School of Public Health, Harvard School of Dental Medicine, the Forsyth Institute, the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, and other disease centers. In addition, I am responsible for teaching fellows who rotate through the Head and Neck Cancer Program, as well as medical students, medical residents, and ear, nose, and throat residents through the DF/BWCC. My current clinical research activities involve the use of an intensive chemoradiotherapy regimen for patients with locally advanced head and neck cancer, with particular attention to radioprotection and cytoprotection. We have initiated a large randomized phase II study with chemoradiotherapy and subcutaneous amifostine. This very important study, conducted across multiple sites, opened and began accruing patients in 2005. We have also started a large phase III study, called the Paradigm Trial, that compares sequential chemoradiotherapy with concomitant chemoradiotherapy. This study will enroll more than 300 patients in different institutions around the country. In other research, we are working with the National Cancer Institute/Cancer Therapy Evaluation program to develop a phase II study examining the use of depsipeptide in head and neck cancer. We will also be looking at new molecules - including Erbitux (cetuximab), lapatinib, ZD6474, and others - for the treatment of head and neck cancer.

Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer. 2021 Jul 16; 160:78-83.
View in: PubMed

A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncol. 2021 Aug; 119:105366.
View in: PubMed

CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021 Jul 15; 27(14):4025-4035.
View in: PubMed

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021 04; 22(4):450-462.
View in: PubMed

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol. 2021 Jun 10; 39(17):1856-1864.
View in: PubMed

[Neurological complications of coitus: Review of literature]. Prog Urol. 2021 Jun; 31(7):392-405.
View in: PubMed

Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab-Reply. JAMA Oncol. 2021 Feb 01; 7(2):309-310.
View in: PubMed

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021 Mar 01; 39(7):840-859.
View in: PubMed

Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2021 Jan 01; 27(1):357.
View in: PubMed

Reply to "Keynote 48: Is it really for everyone?" Oral Oncol. 2021 04; 115:105108.
View in: PubMed

Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 2021 01; 112:105087.
View in: PubMed

Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. Cancer Cell. 2020 Dec 14; 38(6):769-770.
View in: PubMed

Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck. Laryngoscope Investig Otolaryngol. 2020 Dec; 5(6):1063-1069.
View in: PubMed

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570.
View in: PubMed

Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head Neck. 2020 12; 42(12):3670-3677.
View in: PubMed

A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):134-144.
View in: PubMed

Multifocal adult rhabdomyoma of the head and neck: case report and systematic review of the literature. Int J Oral Maxillofac Surg. 2021 Mar; 50(3):327-334.
View in: PubMed

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2020 10 01; 26(19):5140-5152.
View in: PubMed

Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 07; 18(7):873-898.
View in: PubMed

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. J Clin Oncol. 2020 08 20; 38(24):2773-2781.
View in: PubMed

Keynote 48: Is it really for everyone? Oral Oncol. 2020 06; 105:104762.
View in: PubMed

Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 08; 8(8):1075-1084.
View in: PubMed

The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist. 2020 07; 25(7):598-608.
View in: PubMed

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020 07; 31(7):942-950.
View in: PubMed

Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 2020 07; 106:104690.
View in: PubMed

Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2020 06; 105:104676.
View in: PubMed

Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. J Med Econ. 2020 May; 23(5):442-447.
View in: PubMed

Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series. Oral Dis. 2020 Mar; 26(2):325-333.
View in: PubMed

Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-2398.
View in: PubMed

An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectr. 2020 Apr; 4(2):pkz094.
View in: PubMed

Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. Eur J Cancer. 2019 12; 123:138-145.
View in: PubMed

[Sexual dysfunctions after traumatic brain injury: Systematic review of the literature]. Prog Urol. 2019 Sep; 29(11):529-543.
View in: PubMed

Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. Front Oncol. 2019; 9:815.
View in: PubMed

Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral Oncol. 2019 10; 97:82-91.
View in: PubMed

Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer. Cancer Prev Res (Phila). 2019 10; 12(10):689-700.
View in: PubMed

Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. JAMA Oncol. 2019 Aug 01; 5(8):1170-1180.
View in: PubMed

Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019 10; 28(10):1660-1667.
View in: PubMed

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019 09 15; 125(18):3208-3218.
View in: PubMed

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019 09 01; 25(17):5221-5230.
View in: PubMed

Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncol. 2019 08; 95:120-126.
View in: PubMed

A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):132-139.
View in: PubMed

Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. Eur J Cancer. 2019 05; 113:1-9.
View in: PubMed

Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 03 01; 30(3):471-477.
View in: PubMed

Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106.
View in: PubMed

IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019 04; 41(4):959-966.
View in: PubMed

[Use of botulinum toxin A in pelvic floor dysfunctions in the elderly: A review]. Prog Urol. 2019 Mar; 29(4):216-225.
View in: PubMed

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw. 2018 12; 16(12):1429-1440.
View in: PubMed

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018 11 01; 4(11):1583-1588.
View in: PubMed

Toward a Personalized Approach in the Treatment of Salivary Ductal Carcinoma. J Natl Compr Canc Netw. 2018 10; 16(10):1269-1270.
View in: PubMed

Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. JCI Insight. 2018 09 06; 3(17).
View in: PubMed

Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. Ann Oncol. 2018 09 01; 29(9):1980-1986.
View in: PubMed

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
View in: PubMed

Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncol. 2018 10; 85:29-34.
View in: PubMed

Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):137-145.
View in: PubMed

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018 07; 119(2):153-159.
View in: PubMed

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist. 2018 09; 23(9):1079-1082.
View in: PubMed

Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2018 07; 82:83-90.
View in: PubMed

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw. 2018 05; 16(5):479-490.
View in: PubMed

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018 05 01; 29(5):1130-1140.
View in: PubMed

Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treat Rev. 2018 May; 66:64-73.
View in: PubMed

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018 06; 81:45-51.
View in: PubMed

[Cardiovascular adverse effects of antimuscarinics used in the treatment of overactive bladder in the elderly : A review]. Prog Urol. 2018 Jun; 28(7):361-369.
View in: PubMed

Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018 06; 81:1-9.
View in: PubMed

Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018 02 22; 3(4).
View in: PubMed

Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist. 2018 07; 23(7):814-821.
View in: PubMed

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 04 01; 24(7):1546-1553.
View in: PubMed

The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 11; 22(11):1413.
View in: PubMed

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol. 2017 Oct 01; 28(10):2526-2532.
View in: PubMed

Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncol. 2017 10; 73:160-165.
View in: PubMed

Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Front Oncol. 2017; 7:191.
View in: PubMed

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1104-1115.
View in: PubMed

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw. 2017 06; 15(6):761-770.
View in: PubMed

Management of elderly patients with locoregionally confined head and neck cancer. Lancet Oncol. 2017 05; 18(5):e274-e283.
View in: PubMed

[Post-orgasmic illness syndrome]. Prog Urol. 2017 Jun; 27(7):446-448.
View in: PubMed

Highlights in Head and Neck Cancer. JAMA Oncol. 2017 04 01; 3(4):441-442.
View in: PubMed

Advances in Collaborative Practice for Patients With Head and Neck Cancers. J Adv Pract Oncol. 2017 Apr; 8(3):261-265.
View in: PubMed

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol. 2017 May 10; 35(14):1542-1549.
View in: PubMed

The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 03; 22(3):343-350.
View in: PubMed

Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. Oral Oncol. 2017 04; 67:77-82.
View in: PubMed

Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2017 04; 67:61-69.
View in: PubMed

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017 Apr; 56(1):121-128.
View in: PubMed

Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19(2):129-136.
View in: PubMed

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 11 10; 375(19):1856-1867.
View in: PubMed

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 11 10; 34(32):3838-3845.
View in: PubMed

Antiangiogenic agents in head and neck squamous cell carcinoma: Tired of going solo. Cancer. 2016 12 01; 122(23):3592-3595.
View in: PubMed

Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial. Oncologist. 2016 12; 21(12):1522-1529.
View in: PubMed

Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer. 2016 Dec 01; 122(23):3632-3640.
View in: PubMed

Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncol. 2016 10; 61:19-26.
View in: PubMed

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60.
View in: PubMed

Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev. 2016 07; 25(4):344-8.
View in: PubMed

Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer. 2016; 4:32.
View in: PubMed

Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2016 08; 4(8):679-87.
View in: PubMed

The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. Ann Oncol. 2016 08; 27(8):1619-25.
View in: PubMed

Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. Head Neck. 2016 10; 38(10):1530-8.
View in: PubMed

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol. 2016 08; 27(8):1585-93.
View in: PubMed

Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2016 06 15; 22(12):2939-49.
View in: PubMed

Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. Head Neck. 2016 04; 38 Suppl 1:E1618-24.
View in: PubMed

The evolution of an integrated ultrasound curriculum (iUSC) for medical students: 9-year experience. Crit Ultrasound J. 2015 Dec; 7(1):18.
View in: PubMed

Sequential and Concurrent Chemoradiation: State of the Art. Hematol Oncol Clin North Am. 2015 Dec; 29(6):1061-74.
View in: PubMed

Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. JAMA Oncol. 2015 Oct; 1(7):907-15.
View in: PubMed

Optimizing Tobacco Cessation Resource Awareness Among Patients and Providers. J Oncol Pract. 2016 Jan; 12(1):e77-82.
View in: PubMed

Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw. 2015 Sep; 13(9):1140-50.
View in: PubMed

Head and Neck Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Jul; 13(7):847-55; quiz 856.
View in: PubMed

Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol. 2015 Jun 20; 33(18_suppl):LBA6008.
View in: PubMed

Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncol. 2015 Aug; 51(8):751-8.
View in: PubMed

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May; 16(5):583-94.
View in: PubMed

Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Oncol Pract. 2015 Mar; 11(2):151-4.
View in: PubMed

Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res. 2015 Mar 15; 21(6):1447-56.
View in: PubMed

Barriers to clinical trial recruitment in head and neck cancer. Oral Oncol. 2015 Mar; 51(3):203-11.
View in: PubMed

Marital status and head and neck cancer outcomes. Cancer. 2015 Apr 15; 121(8):1273-8.
View in: PubMed

Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Dec; 12(12):1671-80; quiz 1680.
View in: PubMed

Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options. Curr Treat Options Oncol. 2014 Dec; 15(4):595-610.
View in: PubMed

Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Clin Oncol. 2014 Oct 20; 32(30_suppl):100.
View in: PubMed

Optimizing smoking cessation resource awareness among patients and providers. J Clin Oncol. 2014 Oct 20; 32(30_suppl):85.
View in: PubMed

Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014 Oct 28; 111(43):15544-9.
View in: PubMed

Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014 Oct 09; 371(15):1426-33.
View in: PubMed

Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014 Oct; 12(10):1454-87.
View in: PubMed

[Bacterial ecology and resistance to antibiotics in patients with neurogenic overactive bladder treated with intravesical botulinum toxin injections]. Prog Urol. 2014 Oct; 24(12):744-9.
View in: PubMed

New frontiers and treatment paradigms for thyroid carcinoma. Clin Adv Hematol Oncol. 2014 Jul; 12(7 Suppl 14):3-21; quiz 22.
View in: PubMed

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC Cancer. 2014 Jun 28; 14:473.
View in: PubMed

Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol. 2014 Aug 10; 32(23):2408-15.
View in: PubMed

Human papillomavirus-associated adenocarcinoma of the palatine tonsil--reply. Hum Pathol. 2014 Apr; 45(4):895.
View in: PubMed

Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer. 2013 Dec 15; 119(24):4268-76.
View in: PubMed

Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev. 2014 Apr; 40(3):390-404.
View in: PubMed

How to incorporate new tyrosine kinase inhibitors in the treatment of patients with medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3618-20.
View in: PubMed

Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Aug; 11(8):917-23.
View in: PubMed

Larynx preservation: a debate worth preserving. J Clin Oncol. 2013 Sep 01; 31(25):3170.
View in: PubMed

Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment. Laryngoscope. 2013 Dec; 123(12):3066-73.
View in: PubMed

Oral HPV infection in HPV-positive oropharyngeal cancer cases and their spouses. J Clin Oncol. 2013 Jun 20; 31(18_suppl):CRA6031.
View in: PubMed

Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013 Aug 15; 73(16):5195-205.
View in: PubMed

A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncol. 2013 Aug; 49(8):835-41.
View in: PubMed

New developments in thyroid cancer. J Natl Compr Canc Netw. 2013 May; 11(5 Suppl):705-7.
View in: PubMed

Organ preservation for adenoid cystic carcinoma of the larynx. Oncologist. 2013; 18(5):579-83.
View in: PubMed

Human papillomavirus-associated adenocarcinoma of the base of the tongue. Hum Pathol. 2013 Aug; 44(8):1516-23.
View in: PubMed

Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist. 2013; 18(3):288-93.
View in: PubMed

Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013; 18(3):294-300.
View in: PubMed

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013 Mar; 14(3):257-64.
View in: PubMed

Locally advanced head and neck cancer. Am Soc Clin Oncol Educ Book. 2013; 237-44.
View in: PubMed

Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res. 2013 Feb 01; 19(3):524-9.
View in: PubMed

Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread. J Clin Oncol. 2012 Nov 10; 30(32):e321-3.
View in: PubMed

Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res. 2012 Oct 01; 72(19):5004-13.
View in: PubMed

Metabolic syndrome (MetS) in Lebanese patients with schizophrenia receiving atypical antipsychotic drugs. Asian J Psychiatr. 2013 Feb; 6(1):88-9.
View in: PubMed

Genetic polymorphisms modulate the folate metabolism of Brazilian individuals with Down syndrome. Mol Biol Rep. 2012 Oct; 39(10):9277-84.
View in: PubMed

Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol. 2012 Nov; 48(11):1085-9.
View in: PubMed

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol. 2012 Dec; 48(12):1281-8.
View in: PubMed

Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-2398.
View in: PubMed

Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial. Contemp Clin Trials. 2012 Jul; 33(4):700-11.
View in: PubMed

Mucosal melanoma of the head and neck. J Natl Compr Canc Netw. 2012 Mar; 10(3):320-38.
View in: PubMed

Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. Lung Cancer. 2012 May; 76(2):144-9.
View in: PubMed

Swallowing function following postchemoradiotherapy neck dissection: review of findings and analysis of contributing factors. Otolaryngol Head Neck Surg. 2011 Sep; 145(3):428-34.
View in: PubMed

Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial. Cancer. 2012 Apr 01; 118(7):1811-7.
View in: PubMed

Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer. 2011 Jun 07; 104(12):1896-905.
View in: PubMed

Head and neck cancers. J Natl Compr Canc Netw. 2011 Jun 01; 9(6):596-650.
View in: PubMed

Effect of yoga on QOL, cortisol rhythym, and HRV for women with breast cancer undergoing radiotherapy. J Clin Oncol. 2011 May 20; 29(15_suppl):9009.
View in: PubMed

Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e215-22.
View in: PubMed

Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant. 2011 Jun; 46(6):884-91.
View in: PubMed

EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res. 2011 Mar; 8(2):203-12.
View in: PubMed

Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011 May; 22(5):1071-1077.
View in: PubMed

Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):e813-8.
View in: PubMed

Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011 Feb; 12(2):153-9.
View in: PubMed

Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. Cancer. 2011 Jul 01; 117(13):2961-9.
View in: PubMed

Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. Cancer. 2011 Jan 10.
View in: PubMed

Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1405-11.
View in: PubMed

Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):308-14.
View in: PubMed

Thyroid carcinoma. J Natl Compr Canc Netw. 2010 Nov; 8(11):1228-74.
View in: PubMed

Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer. 2010 Oct 15; 116(20):4761-8.
View in: PubMed

Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy. Otolaryngol Head Neck Surg. 2010 Sep; 143(3):367-74.
View in: PubMed

Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: a case series report. Integr Cancer Ther. 2010 Sep; 9(3):284-90.
View in: PubMed

Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. Am J Clin Pathol. 2010 Jul; 134(1):36-41.
View in: PubMed

Medullary carcinoma. J Natl Compr Canc Netw. 2010 May; 8(5):512-30.
View in: PubMed

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010 Jun; 95(6):2664-71.
View in: PubMed

Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis. Laryngoscope. 2010 Feb; 120(2):261-6.
View in: PubMed

beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J Clin Oncol. 2009 Dec 20; 27(36):6222-8.
View in: PubMed

Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010 Feb; 21(2):342-347.
View in: PubMed

Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009 Oct 01; 115(19):4514-23.
View in: PubMed

Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Sep 20; 27(27):4448-53.
View in: PubMed

Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila). 2009 Sep; 2(9):776-81.
View in: PubMed

Induction chemotherapy in head and neck cancer. J Clin Oncol. 2009 Aug 10; 27(23):e52-3; author reply e54.
View in: PubMed

Re: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009 Aug 19; 101(16):1157-8; author reply 1158.
View in: PubMed

Epstein-Barr virus (EBV)-specific immunotherapy in nasopharygneal carcinoma (NPC). J Clin Oncol. 2009 May 20; 27(15_suppl):6025.
View in: PubMed

Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009 Nov 01; 75(3):725-33.
View in: PubMed

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009 May; 20(5):921-7.
View in: PubMed

Clinical Practice Guidance For Radiotherapy Planning Following Induction Chemotherapy In Locoregionally Advanced Head And Neck Cancer . International Journal of Radiation Oncology, Biology, Physics . 2009; In Press.

Seeking alternative biological therapies. The future of targeted molecular treatment. Oral Oncology-In Press. 2008.

Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am. 2008 Dec; 22(6):1155-63, viii.
View in: PubMed

Head and Neck Cancer Update: Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care.(Online CME). 2008.

Seeking alternative biological therapies: the future of targeted molecular treatment. Oral Oncol. 2009 Apr-May; 45(4-5):447-53.
View in: PubMed

Recurrent Squamous Cell Carcinoma of the Tongue. 2008.

Sequential Therapy for the Locally Advanced Larynx and Hypopharynx Cancer Subgroup in TAX 324: Survival, Surgery, and Organ Preservation. Annals of Oncology-In Press. 2008.

A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila). 2008 Oct; 1(5):339-48.
View in: PubMed

Recent advances in head and neck cancer. N Engl J Med. 2008 Sep 11; 359(11):1143-54.
View in: PubMed

Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist. 2008 Aug; 13(8):886-98.
View in: PubMed

Trends in Head and Neck Cancer. The American Journal of Hematology/Oncology. 2008; 7(8):323-324.

Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):1110-8.
View in: PubMed

Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol. 2008 May 20; 26(15_suppl):6007.
View in: PubMed

A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):6024.
View in: PubMed

Sequential therapy for locally advanced larynx and hypopharynx cancer: Subgroup analysis from the TAX 324 Study. J Clin Oncol. 2008 May 20; 26(15_suppl):6031.
View in: PubMed

Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol. 2008 May 20; 26(15_suppl):6001.
View in: PubMed

Sequential therapy for locally advanced larynx and hypopharynx cancer: Subgroup analysis from the TAX 324 Study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6031). 2008.

A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6024). 2008.

Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 6001). 2008.

Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol 26: 2008 (May 20 suppl; abstr 6007). 2008.

Human Papillomavirus Infection and Oropharynx Cancer. Published in "News from S.P.O.H.N.C" Support for People with Oral and Head and Neck Cancer. 2008.

A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008 Mar; 18(3):317-23.
View in: PubMed

Multidisciplinary approach to cancer treatment: focus on head and neck cancer. Dent Clin North Am. 2008 Jan; 52(1):1-17, vii.
View in: PubMed

The MTR A2756G polymorphism is associated with an increase of plasma homocysteine concentration in Brazilian individuals with Down syndrome. Braz J Med Biol Res. 2008 Jan; 41(1):34-40.
View in: PubMed

HPV16 transmission between a couple with HPV-related head and neck cancer. Oral Oncol. 2008 Aug; 44(8):812-5.
View in: PubMed

Effect of folate, vitamin B6, and vitamin B12 intake and MTHFR C677T polymorphism on homocysteine concentrations of renal transplant recipients. Transplant Proc. 2007 Dec; 39(10):3163-5.
View in: PubMed

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25; 357(17):1705-15.
View in: PubMed

Novel agents for the treatment of mucositis. J Support Oncol. 2007 Oct; 5(9 Suppl 4):33-9.
View in: PubMed

Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1369-76.
View in: PubMed

Human Papillomavirus Infection and Oropharyngeal Cancer.(Online CME). 2007.

Trends in Head and Neck Cancer. The American Journal of Hematology/Oncology. 2007; Vol 6. No 4(4):187-188.

Behavior of oral squamous cell carcinoma in subjects with prior lichen planus. Otolaryngol Head Neck Surg. 2007 Mar; 136(3):401-4.
View in: PubMed

Retropharyngeal nodes in hypopharynx cancer on positron emission tomography. J Clin Oncol. 2007 Feb 10; 25(5):599-601.
View in: PubMed

Oral Mucous Membrane Macrobiotica in Health and Oral Squamous Cell Carcinoma. Grand Rounds in Oral-Systemic Medicine. 2007; 2(1):12-8.

Translational studies of depsipeptide, a histone deacetylase (HDAC) inhibitor in patients with head and neck cancer [abstract]. Proc Am Assoc Cancer Res 48: A3524 . 2007.

Phase I study of panitumumab, chemotherapy, and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results. . Proc Am Soc Clin Oncol 1/1/2007; 25: Abstr #6083. 2007.

Swallowing function after IMRT and chemotherapy for head and neck cancer. Proc Am Soc Clin Oncol 1/1/2007; 25: Abstr #6046 . Proc Am Soc Clin Oncol 1/1/2007; 25: Abstr #6046. 2007.

Head and Neck Carcinoma: American College of Physicians (ACP) On-line publication, Physicians Information and Education Resource (PIER). . Online. 2007.

Combination of angiotensin-converting enzyme and methylenetetrahydrofolate reductase gene polymorphisms as determinant risk factors for chronic allograft dysfunction. Transplant Proc. 2007 Jan-Feb; 39(1):78-80.
View in: PubMed

Clinical and translational studies of depsipeptide, a histone deacetylase inhibitor, in patients with squamous cell carcinoma of the head and neck: New York Cancer Consortium Trial P6335 [abstract]. Proc Am Soc Clin Oncol 1/1/2007; 25: A6065 . 2007.

Changing Paradigms in the Treatment of Squamous Cell Carcinoma of the Head and Neck. (Online CME). 2006.

[Pilomatricoma or calcifying epithelioma of Malherbe. A pediatric review of 89 cases]. Ann Chir Plast Esthet. 2007 Feb; 52(1):39-42.
View in: PubMed

Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs. 2006 Sep; 11(3):461-7.
View in: PubMed

Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol. 2007 Mar; 43(3):289-300.
View in: PubMed

PET/CT imaging in patients with suspected recurrence of pancreatic cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14137.
View in: PubMed

Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006 Jun; 132(6):678-81.
View in: PubMed

Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer. Otolaryngol Head Neck Surg. 2006 Jun; 134(6):916-22.
View in: PubMed

Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1036-44.
View in: PubMed

Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006 May; 132(5):526-31.
View in: PubMed

Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol. 2006 Apr; 29(2):153-7.
View in: PubMed

Current and future directions in the treatment of squamous cell carcinoma of the head and neck: multidisciplinary symposium on head and neck cancer. Expert Opin Ther Targets. 2006 Apr; 10(2):333-6.
View in: PubMed

Integrating novel agents in the curative treatment of head and neck cancer. Exp. Rev, Anti. Ther. 2006; 6(2):157-9.

Integrating novel agents into the curative treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006 Feb; 6(2):157-9.
View in: PubMed

Cetuximab in squamous cell carcinoma of the head and neck. Am. J. Onc. Rev. 2006; 1(1).

Use of Peripheral Blood Monocytes (PBM) to Define Changes in Gene Expression Associated with Amifostine Treatment And Their Association With Oral Mucositis (OM) In Patients Being Treated With Chemoradiotherapy For Squamous Cell Carcinoma of the Head and Neck (SCCHN). American Society of Therapeutic Radiation Oncology (ASTRO) Meeting. 2006.

A phase III trial of TPF vs. PF Induction Chemotherapy Followed by chemoradiotherapy in Locally Advanced SCCHN. Special Session ASCO. 2006.

The Evolution of induction chemotherapy and sequential therapy for locally advanced squamous cell cancer of the head and neck. ASCO Educational Book. 2006; 346-52.

A Phase III Open-Label, Long-Term Safety Study of Cevimeline Hydrochloride in Patients with Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region. ASTRO Meeting. 2006.

Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Oct 01; 23(28):6976-81.
View in: PubMed

Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol. 2005 Aug; 28(4):371-8.
View in: PubMed

Pilot study of celecoxib in oral premalignant lesions (OPLs): Preliminary results. J Clin Oncol. 2005 Jun; 23(16_suppl):1025.
View in: PubMed

Rate of complete pathological responses (pCR) to docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2005 Jun; 23(16_suppl):5511.
View in: PubMed

Chemoradiation-induced cell loss in human submandibular glands. Laryngoscope. 2005 Jun; 115(6):958-64.
View in: PubMed

Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer. Am J Clin Oncol. 2005 Feb; 28(1):104.
View in: PubMed

Concomitant Chemoradiation Using Weekly Carboplatin/Paclitaxel With or Without Daily Subcutaneous Amifostine in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck. ASTRO meeting 2005. Denver , CO. IJROBP supplement. 2005; 63, 2:2229.

Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol. 2005 Jan; 41(1):70-6.
View in: PubMed

The Evolution of Induction Chemotherapy in Locally Advanced Squamous Cell Cancer of the Head and Neck: The New Paradigm of Sequential Therapy. Head and Neck Cancer, Adelstein, D (ed). 2005; 171-86.

Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004 Dec; 31(6):778-85.
View in: PubMed

Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer. Laryngoscope. 2004 Nov; 114(11):1924-31.
View in: PubMed

Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004 Oct; 26(10):890-6.
View in: PubMed

A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5548.
View in: PubMed

Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5540.
View in: PubMed

Interleukin-8 (IL-8) serum levels and squamous cell cancer of the head and neck (SCCHN). J Clin Oncol. 2004 Jul 15; 22(14_suppl):9716.
View in: PubMed

Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5600.
View in: PubMed

Interleukin-8 (IL-8) Serum Levels and Squamous Cell Cancer of the Head and Neck (SCCHN). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)(July 15 Supplement). 2004; 22 No14S:9716.

A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition)(July 15 Supplement). 2004; 22, No 14S:5548.

Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition) (July 15 Supplement). 2004; 22, No 14S:5540.

A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res. 2004 Jul 15; 10(14):4680-7.
View in: PubMed

Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition)(July 15 Supplement). 2004; 22, No 14S:5600.

The Role of Epidermal Growth Factor Receptor Inhibitors In Head And Neck Cancer. Am. J. Onc. Rev. 2004; 3(7).

RE: Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. N. Engl. J. Med. 2004; 350(10):1051-2.

Nonsurgical treatment of laryngeal cancer. N Engl J Med. 2004 Mar 04; 350(10):1049-53; author reply 1049-53.
View in: PubMed

Respiratory mechanics and pleural remodelling in pleurodesis induced by barium sulphate. Respir Physiol Neurobiol. 2004 Feb 25; 139(3):271-80.
View in: PubMed

HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004 Feb 01; 10(3):944-6.
View in: PubMed

RE: Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double blind, placebo-controlled trial. Lancet. 2004; 363(9402):79-80.

Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet. 2004 Jan 03; 363(9402):79-80; author reply 81-2.
View in: PubMed

A method for rating charts to identify and classify patients with medically unexplained symptoms. Psychother Psychosom. 2004 Jan-Feb; 73(1):36-42.
View in: PubMed

Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Semin Oncol. 2003 Dec; 30(6 Suppl 18):84-8.
View in: PubMed

Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003 Oct; 39(7):724-7.
View in: PubMed

Spontaneous long-term remission in a patient with premature ovarian failure. Endocr Pract. 2003 Sep-Oct; 9(5):380-3.
View in: PubMed

Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. Cancer Chemother Pharmacol. 2003 Oct; 52(4):303-6.
View in: PubMed

Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):331-8.
View in: PubMed

Progress and perspectives in chemoprevention of head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):339-55.
View in: PubMed

Palliative Chemotherapy in Patients With Salivary Gland Neoplasms: Review of The Literature and Preliminary Reports of Two Recently Performed Phase II Studies With Single Agents Herceptin And Gemcitabine. Clinical Advances in Hematology & Oncology. 2003; (1):226-8.

Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. Clin Adv Hematol Oncol. 2003 Apr; 1(4):226-8.
View in: PubMed

Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2003 Mar 15; 97(6):1589; author reply 1590.
View in: PubMed

Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003 Jan 15; 97(2):412-8.
View in: PubMed

A Phase II Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Head and Neck Squamous Cell Carcinoma (HNSCC): Clinical activity and post-treatment modulation of Rb phosphorylation. Proc. Am. Soc. Clin. Oncol. (abstr 800) (Poster discussion session). 2003; 22:200.

Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist. 2003; 8(1):35-44.
View in: PubMed

49 year old male with locally advanced squamous cell carcinoma of the head and neck: the case for sequential chemoradiotherapy programs. Clin Adv in Hematol Oncol. 2003; 1(1):58-61.

A 49-year-old male with locally advanced squamous cell carcinoma of the head and neck: the case for sequential chemoradiotherapy. Clin Adv Hematol Oncol. 2003 Jan; 1(1):58-60; discussion 61-2.
View in: PubMed

Docetaxel, Cisplatin and 5-fluouracil (TPF) based induction chemotherapy for locally advanced head and neck cancer: long term survival and salvage. (ASCO Proc). 2002; 21:960.

A Phase I/II Trial Of Concurrent Docetaxel And Concomitant Boost Radiation Therapy For Patients With Squamous Cell Cancer Of The Head And Neck Following Induction Chemotherapy: A Sequential Combined Modality Approach. (ASCO Proc). 2002; 21:2561.

Immunoguided lymph node dissection in colorectal cancer: a new challenge? World J Surg. 2001 Dec; 25(12):1495-8; discussion 1499.
View in: PubMed

Regression and clonally distinct recurrence of human immunodeficiency virus related Burkitt-like lymphoma during antiretroviral therapy. Leuk Lymphoma. 2001 Sep-Oct; 42(5):1125-31.
View in: PubMed

Self-assembly of mesoscopically ordered chromatic polydiacetylene/silica nanocomposites. Nature. 2001 Apr 19; 410(6831):913-7.
View in: PubMed

Segmental resection for recurrent carcinoma of the esophagus. Isr Med Assoc J. 2001 Mar; 3(3):228-9.
View in: PubMed

Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer. 2001 Feb 01; 91(3):548-54.
View in: PubMed

Effects of intravenous gamma immunoglobulins treatment on severe peritonitis in rats. Int J Surg Investig. 2001; 2(6):433-42.
View in: PubMed

Antineoplastic Drug Development. The Chemotherapy Source Book, Perry MC (ed). 2001.

Superselective Intraarterial Cisplatin In Patients With Squamous Cell Carcinoma Of The Head And Neck: University Of Maryland Experience. (ASCO Proc). 2001; 20:2562.

A Phase II Trial of Taxotere, Topotecan Combination Chemotherapy in Patients with Recurrent, Metastatic SCC of the Head and Neck. (AACR). 2001.

Restriction landmark genomic scanning of mouse liver tumors for gene amplification: overexpression of cyclin A2. Biochem Biophys Res Commun. 2000 Jul 21; 274(1):188-96.
View in: PubMed

The effects of somatostatin and octreotide on experimental and human acute pancreatitis. J Lab Clin Med. 2000 Feb; 135(2):112-21.
View in: PubMed

Identification of lymph node metastases in recurrent colorectal cancer. Recent Results Cancer Res. 2000; 157:281-92.
View in: PubMed

Pretreatment Hemoglobin (Hgb) Is Associated With Response to Chemoradiation Therapy (CRT) in Patients with Advanced, Unresectable Squamous Cell Carcinoma of the Head and Neck (SCCHN). (ASCO Proc)(Poster discussion session). 2000; 19:1646.

[Photodynamic therapy for dysphagia due to esophageal carcinoma]. Harefuah. 1999 Nov 15; 137(10):441-4, 512.
View in: PubMed

Erythema nodosum after smoke inhalation-induced bronchiolitis obliterans organizing pneumonia. Crit Care Med. 1999 Jun; 27(6):1214-6.
View in: PubMed

Continuous intravenous octreotide treatment for acute experimental pancreatitis. Digestion. 1999 Mar-Apr; 60(2):125-31.
View in: PubMed

Anchoring the diaphragm after blunt trauma. Injury. 1999 Jan; 30(1):57-8.
View in: PubMed

Delayed Use of Granulocyte Colony-Stimulating Factor Following Autologous Peripheral Blood Stem Cell Transplantation Does Not Affect Engraftment or Hospital Stay. Blood. 1999; 10(Supp 1):4821.

Single-injection gamma probe-guided sentinel lymph node detection in 40 melanomatous lymphadenectomies. Ann Plast Surg. 1998 Oct; 41(4):397-401.
View in: PubMed

In vitro and in vivo effects of photodynamic therapy on murine malignant melanoma. Ann Surg Oncol. 1998 Apr-May; 5(3):241-7.
View in: PubMed

Localization of monoclonal antibody CC49 in colonic metastasis from renal cell carcinoma. Eur J Surg Oncol. 1998 Apr; 24(2):149-51.
View in: PubMed

Genomic imprinting and Igf2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice. Cancer Res. 1997 Oct 15; 57(20):4615-23.
View in: PubMed

Impact of early orchidopexy on testicular growth. Br J Urol. 1997 Aug; 80(2):334-5.
View in: PubMed

Preoperative pulmonary function tests do not predict outcome after coronary artery bypass. Conn Med. 1997 Jun; 61(6):327-32.
View in: PubMed

Endometriosis in abdominal scars: a diagnostic pitfall. Am Surg. 1996 Dec; 62(12):1042-4.
View in: PubMed

[Hand burns in children. Retrospective study of 137 cases from 1973-1982 representing 177 hands]. Chir Pediatr. 1984; 25(1):43-7.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top